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Abstract
Background: The dengue virus is the most significant arthropod-borne human pathogen, and an increasing
number of cases have been reported over the last few decades. Currently neither vaccines nor drugs against the
dengue virus are available. NS5 methyltransferase (MTase), which is located on the surface of the dengue virus and
assists in viral attachment to the host cell, is a promising antiviral target. In order to search for novel inhibitors of
NS5 MTase, we performed a computer-aided virtual screening of more than 5 million commercially available
chemical compounds using two approaches: i) structure-based screening using the crystal structure of NS5 MTase
and ii) ligand-based screening using active ligands of NS5 MTase. Structure-based screening was performed using
the LIDAEUS (LIgand Discovery At Edinburgh UniverSity) program. The ligand-based screening was carried out
using the EDULISS (EDinburgh University LIgand Selection System) program.
Results: The selection of potential inhibitors of dengue NS5 MTase was based on two criteria: the compounds must
bind to NS5 MTase with a higher affinity than that of active NS5 MTase ligands, such as ribavirin triphosphate (RTP)
and S-adenosyl-L-homocysteine (SAH); and the compounds must interact with residues that are catalytically
important for the function of NS5 MTase. We found several compounds that bind strongly to the RNA cap site and
the S-adenosyl-L-methionine (SAM) binding site of NS5 MTase with better binding affinities than that of RTP and SAH.
We analyzed the mode of binding for each compound to its binding site, and our results suggest that all compounds
bind to their respective binding sites by interacting with, and thus blocking, residues that are vital for maintaining the
catalytic activity of NS5 MTase.
Conclusions: We discovered several potential compounds that are active against dengue virus NS5 MTase through
virtual screening using structure-based and ligand-based methods. These compounds were predicted to bind into
the SAM binding site and the RNA cap site with higher affinities than SAH and RTP. These compounds are
commercially available and can be purchased for further biological activity tests.
Background
Dengue fever is an ancient disease that was first recorded
in a Chinese encyclopedia of diseases and symptoms pub-
lished during the Chin Dynasty (265 to 420 AD) [1].
Referred to as “water poison” in ancient Chinese medical
literatures due to its association with flying insects bred
in clean water, modern science has now confirmed that
dengue fever is a viral disease transmitted between
human hosts by Aedes mosquitoes, particularly Aedes
aegypti. The ability of Aedes aegypti to adapt well to
urban living environments plays a significant role in the
outbreak of dengue fever [2]. Currently, dengue fever is
the most important tropical infectious disease after
malaria, and more than 100 countries have reported
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any medium, provided the original work is properly cited.infections, especially countries in tropical and subtropical
regions [3]. An estimated 100 million cases of dengue
fever occur annually. Of these, 500,000 cases require hos-
pitalization, and 25,000 are fatal [1,4], particularly in
developing and underdeveloped countries where access
to healthcare facilities is limited.
In general, the dengue virus (DV) is a plus-strand RNA
virus of the Flavivirus genus of the Flaviviridae family
[5]. The DV has an approximately 50 nm envelope and
contains a 10.7 kb single strand RNA that is translated
into a single polyprotein followed by co-translational clea-
vage into 10 mature proteins. These 10 mature proteins
consist of three structural proteins (capsid (c), premem-
brane (prM), envelope (E)) and seven nonstructural pro-
teins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5)
(Figure 1) [6]. The nonstructural proteins are involved in
evading innate immune responses, virion assembly, and
the replication of the genome. The structural proteins
play a role in the formation of the viral particle [6-8]. To
date, the enzymatic activities of NS3 and NS5 are the
best characterized among the non-structural DV proteins.
Based on a number of studies, the methyltransferase
(MTase) domain of the DV non-structural protein NS5
(NS5 MTase) is thought to be a promising antiviral target
[9-12].
The stability of dengue viral mRNA and the efficient
translation are closely related to its cap structure. The 5′
end of the dengue RNA has a type 1 cap structure (me
7-
GpppA-me
2), whose formation requires NS3 and NS5
enzymatic reactions [13]. NS5 MTase methylates the gua-
nosine cap at the N7 position by transferring a methyl
group from S-adenosyl-L-methionine (SAM) followed
by methylation of the 2′-OH position of the first ribose
nucleotide [14]. A side product, S-adenosyl-L-homocys-
teine (SAH), is produced from N7 and 2′-O methylations
[15]. Although MTase exhibits two distinct methylations, it
has only single SAM binding site in its crystal structure
[16]. It has been suggested that the substrate GpppA-RNA
must be re-positioned to accept the N7 and 2′-O methyl
groups from SAM during the two methylation reactions.
There are two binding sites connected by a Y-shaped cleft.
The first site is the SAM (methyl donor) binding site,
and the second site is a shallow pocket of the RNA cap site
[17].
NS5 MTase has a globular shape with a seven-stranded
central b-sheet surrounded by six helices (Figure 2a). The
crystal structure of NS5 MTase with SAH and a nucleo-
side analogue, ribavirin triphosphate (RTP), is shown in
Figure 2b. Based on the crystal structure, there are two
complexes assigned to two binding sites. One site is for
5’
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Figure 1 Schematic figure of Flavivirus RNA and its translation into proteins involved in the DV lifecycle.
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situated on an N-terminal subdomain for guanosine-5′-tri-
phosphate (GTP) analogues [18].
Currently, there are no vaccines or drugs to inhibit DV
replication and transmission. The presence of four sero-
types of the DV (DV1 – DV4) has hampered the efforts
to develop effective drugs or vaccines against the DV
[19]. Infection with one DV serotype will result in life-
long immunity to that serotype; however, sequential
infection by other serotypes of the DV will result more
severe symptoms. Dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS) typically occur through
antibody-mediated disease enhancement (ADE), either
from previous DV infection [20] or from vaccine-induced
ADE [21]. The unique properties of the DV make the
design and discovery of effective vaccines and drugs
against the DV extremely challenging.
In this work, we performed a computer-aided virtual
screen of more than 5 million commercially available che-
mical compounds to find potential inhibitors of NS5
MTase. We utilized two different approaches: i) structure-
based virtual screening using the crystal structure of NS5
MTAse [PDB:1R6A] and ii) ligand-based virtual screening
using active ligands of NS5 MTase (ribavirin and SAH).
Structure-based compound screening was performed
using the LIDAEUS (LIgand Discovery At Edinburgh Uni-
verSity) program [22], which maps the active site of the
receptor and screens it against approximately 5 million
commercially available chemical compounds in its data-
base. Meanwhile, ligand-based compound screening was
carried out using the EDULISS (EDinburgh University
LIgand Selection System) program [23], which utilizes
known natural substrates of NS5 MTase to find structu-
rally similar compounds from its database. We discovered
several compounds that fit into the two binding sites of
NS5 MTase with a higher binding affinity than its active
ligands. These compounds can be further tested to con-
firm their biological activities against the DV.
Results
In this work, we employed two different approaches to vir-
tually screen potential inhibitors against dengue virus NS5
MTase. A structure-based virtual screen was performed
using LIDAEUS to generate a map based on the NS5
MTase binding site. This map was used to screen approxi-
mately 5 million compounds in the LIDAEUS database for
those that fit into the binding site map. Meanwhile, a
ligand-based virtual screen was done using the UFSRAT
(Ultra Fast Shape Recognition with Atom Types) algo-
rithm implemented in EDULISS to search for compounds
that are structurally similar to the two active ligands of
NS5 MTase, RTP and SAH.
We then selected the top 500 highest ranked com-
pounds from the EDULISS and LIDAEUS screenings for
further molecular docking experiments using AutoDock
Vina. Even though LIDAEUS analyzed the initial docking
of millions of compounds in its database to methyltrans-
ferase, it uses a course-grained docking tool that is essen-
tially rigid body docking (rigid ligand and rigid protein).
This is the only approach available for working with large
datasets. LIDAEUS tries to get around the rigid-rigid lim-
itation by representing multiple conformers of a small
RTP
SAH
AB
Figure 2 Structure of dengue NS5 MTase [PDB:1R6A]. (a) Ribbon representation of NS5 MTase; a-helix is illustrated in red and b-sheet is
illustrated in yellow. (b) Surface representation of NS5 MTase with RTP and SAH inside the RNA cap site and SAM binding site, respectively.
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the top small molecules, more accurate analysis/docking
trials were performed using AutoDock Vina for flexible
ligand docking. This is much more computationally
expensive than the rigid-rig i dd o c k i n gc a r r i e do u tw i t h
LIDAEUS. Furthermore, EDULISS does not have the same
automated docking functionality as LIDAEUS. AutoDock
Vina was run to rank the proposed compounds from the
EDULISS screen based on their binding affinities.
In total, we docked 2000 unique compounds from the
LIDAEUS screen for molecules that potentially bind to
SAM binding site (500 compounds) and RNA cap site
(500 compounds) and from the EDULISS screen using
RTP (500 compounds) and SAH (500 compounds) as tem-
plates. Binding affinity calculations for all 2000 com-
pounds were carried out using an algorithm implemented
in AutoDock Vina. We identified 40 compounds with the
highest binding affinities to the SAM and RNA cap sites
(Table 1) that have stronger binding to their respective
binding sites than RTP and SAH. The rational basis of
selecting compounds with binding affinities higher than
that of RTP and SAH is that only compounds that bind to
NS5 MTase with a higher affinity than its natural sub-
strates can be developed as potential inhibitors. Only the
compounds that are ranked first for the SAM and RNA
cap sites will be discussed in detailed.
Validation of the docking
In molecular docking, the size and center of the coordi-
nates of the grid box need to be validated in order to
ensure that ligands bind to the binding pocket in the cor-
rect conformation. In this work, docking validation was
performed by redocking co-crystallized RTP and SAH
into their respective binding sites. We found that the
binding conformations of redocked RTP and SAH repro-
duced the binding modes of the co-crystallized ligands
with binding affinities of -5.6 kcal/mol and -7.3 kcal/mol
for RTP and SAH, respectively (Figure 3).
The RNA cap site of NS5 MTase is an open and shal-
low pocket. There are three polar interactions formed
between RTP and the RNA cap site (Figure 3a). The
backbone oxygen of Leu20 forms a hydrogen bond with
the N4 nitrogen of RTP, and the backbone oxygen of
Asn18 forms a hydrogen bond with the N9 nitrogen.
Both N4 and N9 are located on a pseudobase moiety of
RTP, which mimics the interaction between the guanine
moiety of GDPMP (a GTP analogue) and NS5 MTase
[15]. The backbone nitrogen of Lys29 forms a hydrogen
bond with the O1P oxygen of RTP that further stabilizes
RTP binding. A hydrophobic interaction between the
pseudobase moiety of RTP and Leu17 of the RNA cap
site was observed. The aromatic ring of Phe25 forms an
aromatic stacking interaction with the pseudobase ring of
RTP (Figure 3a).
The SAM binding pocket is thought to be more closed
than the RNA cap site. The backbone oxygen of Ser56 and
the nitrogen of Gly86 interact with the SAH molecule by
forming hydrogen bonds with the carboxylic atoms of the
homocysteine moiety of SAH. The carbonyl atom of the
Asp146 side chain also forms a hydrogen bond with the
amino group of the homocysteine moiety of SAH. In addi-
tion, there were four hydrophobic interactions between
the hydrophobic side chains of Thr104, Lys105, Val132
and Ile147 in the SAM binding pocket with the adenosine
moiety of the SAH molecule (Figure 3b).
Dong and colleagues [24] performed a biochemical and
genetic characterization of the dengue virus NS5 MTase
and identified important interactions between SAH and
the surrounding residues of the SAM binding site.
Asp131 interacts with the amino group of the adenosine
moiety of SAH, while a hydrogen bond exists between
the side chain of His110 and 2′-OH of the ribose moiety.
Four residues (His110, Lys105, Asp131 and Ile147) were
found to play an important role in N7 and 2-O′ methyla-
tions. That report emphasized the importance of the
SAM binding site for both methylations. There are slight
differences between our result and the result of Dong et
al. in terms of the amino acids that are involved in the
interaction between SAH and the SAM binding site. We
identified three hydrogen bonds formed between SAH
and Ser56, Gly86 and Asp146, which are not identified in
Dong’s work. However, our results confirm that Lys105
and Ile147 form hydrophobic interactions with SAH.
Inhibitors bound to RNA cap site
We performed molecular docking on 500 compounds
obtained from the ligand-based EDULISS screen. These
500 compounds were ranked based on their binding affi-
nities. The top ten compounds with binding affinites for
the RNA cap site that are more negative than that of
R T Pa r el i s t e di nT a b l e1 .T h et w oc o m p o u n d st h a t
showed the strongest affinites for the RNA cap site of
NS5 MTase were SPH1-103-799 and SPH1-101-102,
each with a binding affinity of -7.8 kcal/mol. Meanwhile,
500 compounds from the structure-based LIDAEUS
screen were also docked into the RNA cap site. The top
10 compounds with more negative binding affinities than
that of RTP, indicating stronger binding, are listed in
Table 1. The compound with the highest affinity discov-
ered through the LIDAEUS screen was 28SPH1-115-917,
with a binding affinity of -7.9 kcal/mol.
Compound SPH1-103-799 (Figure 4a) forms three
hydrogen bonds between oxygen O35 of the carbonyl
group and the backbone nitrogen of Lys22, oxygen O36
of the hydroxyl group and the backbone oxygen of
Leu20, and oxygen O30 of the hydroxyl group and the
backbone oxygen of Asn18. Hydrophobic interactions
occur between the aromatic rings of SPH1-103-799 and
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potential inhibitor, compound SPH1-101-102 (Figure
4b), also forms three hydrogen bonds between the oxy-
gen O21 of the carbonyl group with the backbone nitro-
gen of Lys14, oxygen O22 with the side chain oxygen of
Ser150, and oxygen O13 with the side chain nitrogen of
Lys22. In contrast with compound SPH1-103-799, only
one residue is involved in hydrophobic interaction
between SPH1-101-102 and the RNA cap site at Phe25.
Meanwhile, compound 28SPH1-115-917 (Figure 4c)
forms a hydrogen bond between oxygen O18 of the car-
bonyl group and the side chain oxygen of Ser150. Like-
wise, the side chain nitrogen atom of Lys22 creates a
hydrogen bond with oxygen O5. Two hydrophobic inter-
actions are formed between the aromatic rings of
28SPH1-115-917 and Phe25 and Pro152.
Benarroch et al. [18], who studied the binding of RTP
with the RNA cap site of NS5 MTase, suggested a list of
residues that are significantly important for ligand binding:
Lys14, Leu17, Asn18, Leu20, Phe25, Lys29, Ser150, Ser151,
Table 1 Binding affinity and predicted binding pocket of docked compounds
Compound ID Virtual screening Binding pocket Binding affinity (kcal/mol)
SPH1-103-799 EDULISS RNA cap -7.8
SPH1-101-102 EDULISS RNA cap -7.8
SPH1-027-074 EDULISS RNA cap -7.7
SPH1-014-180 EDULISS RNA cap -7.6
SPH1-047-692 EDULISS RNA cap -7.6
SPH1-000-259 EDULISS RNA cap -7.6
SPH1-013-274 EDULISS RNA cap -7.5
SPH1-013-272 EDULISS RNA cap -7.5
SPH1-013-273 EDULISS RNA cap -7.5
SPH1-013-271 EDULISS RNA cap -7.5
28SPH1-115-917 LIDAEUS RNA cap -7.9
35SPH1-021-288 LIDAEUS RNA cap -7.8
28SPH1-185-015 LIDAEUS RNA cap -7.8
28SPH1-149-718 LIDAEUS RNA cap -7.6
28SPH1-026-800 LIDAEUS RNA cap -7.6
28SPH1-024-902 LIDAEUS RNA cap -7.5
28SPH1-081-432 LIDAEUS RNA cap -7.5
29SPH1-063-033 LIDAEUS RNA cap -7.3
28SPH1-024-902 LIDAEUS RNA cap -7.3
28SPH1-348-781 LIDAEUS RNA cap -7.3
SPH1-007-088 EDULISS SAM -11.4
SPH1-111-460 EDULISS SAM -11.4
SPH1-177-492 EDULISS SAM -11.0
SPH1-020-782 EDULISS SAM -10.6
SPH1-016-182 EDULISS SAM -10.5
SPH1-159-983 EDULISS SAM -10.5
SPH1-129-393 EDULISS SAM -10.4
SPH1-031-492 EDULISS SAM -10.3
SPH1-107-521 EDULISS SAM -10.3
SPH1-297-578 EDULISS SAM -10.3
25SPH1-103-433 LIDAEUS SAM -10.0
25SPH1-103-428 LIDAEUS SAM -9.9
42SPH1-001-864 LIDAEUS SAM -9.8
25SPH1-103-428 LIDAEUS SAM -9.8
42SPH1-001-481 LIDAEUS SAM -9.5
42SPH1-001-925 LIDAEUS SAM -9.5
25SPH1-108-370 LIDAEUS SAM -9.3
42SPH1-013-393 LIDAEUS SAM -9.2
25SPH1-102-225 LIDAEUS SAM -9.1
25SPH1-102-901 LIDAEUS SAM -8.2
Lim et al. BMC Bioinformatics 2011, 12(Suppl 13):S24
http://www.biomedcentral.com/1471-2105/12/S13/S24
Page 5 of 12Ser150
Pro152
Ser214 Asn18
Leu17
Leu20
Phe25
Lys22
SPH1-103-799
SPH1-101-102
28SPH1-115-917
Ser150
Lys14
Phe25
Lys22
Pro152
Ser150
Phe25
Lys22
AB
C D
Figure 4 Binding conformations of three compounds inside the RNA cap site. (a) Compound SPH1-103-799 is shown in green carbons. (b)
Compound SPH1-101-102 is shown in turquoise carbons. (c) Compound 28SPH1-115-917 is shown in orange carbons. Residues with
hydrophobic contacts with the ligands are labeled in red. Hydrogen bonds are drawn as dashed lines. (d) Superimposition of three discovered
compounds and RTP. Crystallized conformation of RTP is shown in yellow carbons, compound SPH1-103-799 is shown in green carbons,
compound SPH1-101-102 is shown in turquoise carbons, and compound 28SPH1-115-917 is shown in orange carbons
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Figure 3 R e d o c k i n go fR T Pa n dS A Hi n t oR N Ac a ps i t ea n dS A Mb i n d i n gs i t e .(a) Crystallized conformation of RTP is shown in yellow
carbons. The best redocked pose of RTP is shown in green carbons. (b) Crystallized conformation of SAH is shown in yellow carbons. The best
redocked conformation of SAH is shown in green carbons. Residues with hydrophobic contacts with RTP and SAH are labeled in red and
hydrogen bonds are drawn as dashed lines
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Page 6 of 12Pro152, Glu408, and Gly409. Our results show that com-
pound SPH1-103-799 binds to the RNA cap site by form-
ing interactions with eight residues: Leu17, Asn18, Leu20,
Lys22, Phe25, Ser150, Pro152, and Ser214. These residues,
with the exception of Lys22 and Ser214, interact with RTP
in the crystal structure of NS5 MTase. Compounds SPH1-
101-102 and 28SPH1-115-917 have fewer interactions
with the RNA cap site. Only four residues are involved in
the binding of these two compounds. Even though com-
pounds SPH1-101-102 and 28SPH1-115-917 have fewer
interactions with the RNA c a ps i t ec o m p a r e dt oR T P ,
these compounds show stronger binding to the RNA cap
site than RTP. There are several possible explanations for
this effect: i) compound SPH1-101-102 creates three
hydrogen bonds with the RNA cap site at different parts
of the ligand, thus distributing the strength of the binding
all over the ligand molecule; ii) compound 28SPH1-115-
917 forms an aromatic stacking interaction with Phe25
that mimics the interaction of the pseudobase moiety of
RTP with Phe25, and the ligand binding is strengthened
by two hydrogen bonds with Lys22 and Ser150.
Inhibitors bound to SAM binding site
After 500 compounds obtained from the ligand-based
EDULISS screen were docked into the SAM binding site,
10 compounds with higher binding affinities for NS5
MTase than that of SAH were tabulated (Table 1). The
two compounds with the strongest affinity for the SAM
binding site were SPH1-007-088 and SPH1-111-460,
each of which had a binding affinity of -11.4 kcal/mol.
Meanwhile, 500 compounds obtained from the structure-
based LIDAEUS screen were also docked into the SAM
binding site, and the 10 best compounds are listed in
Table 1. The best binder was compound 25SPH1-103-
433 (-10.0 kcal/mol).
Compound SPH1-007-088 (Figure 5a) forms two
hydrogen bonds and several hydrophobic interactions
with residues inside the SAM binding site. Two hydrogen
Gly86
Arg84
Ser56
Glu111
Gly83
Lys105
Ile147
Asp131
Val132
Phe133
SPH1-007-088
Asp146
Lys105
SPH1-111-460
Trp87
Gly86
Ser56
Arg84
Gly83
Cys82
Gly81
Lys105
Phe133
Asp131 Thr104
Ile147
25SPH1-103-433
AB
CD
Figure 5 Binding conformations of three compounds inside the SAM binding site. (a) Compound SPH1-007-088 is shown in green
carbons. (b) Compound SPH1-111-460 is shown in turquoise carbons. (c) Compound 25SPH1-103-433 is shown in orange carbons. Residues with
hydrophobic contacts with the ligands are labeled in red. Hydrogen bonds are drawn as dashed lines. (d) Superimposition of three discovered
compounds and SAH. Crystallized conformation of SAH is shown in yellow carbons, compound SPH1-007-088 is shown in green carbons,
compound SPH1-111-460 is shown in turquoise carbons, and compound 25SPH1-103-433 is shown in orange carbons
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and the backbone nitrogen of Gly86 with oxygen O17. In
addition, several hydrophobic interactions are formed
between compound SPH1-007-088 with the hydrophobic
side chains of Gly83, Arg84, Lys105, Glu111, Asp131,
Val132, Phe133, and Ile147. As for compound SPH1-
111-460 (Figure 5b), there are two hydrogen bonds
formed with the SAM binding site. Oxygen O1 of SPH1-
111-460 creates a hydrogen bond with the side chain
oxygen of Asp146, whereas oxygen O33 forms a hydro-
gen bond with the backbone nitrogen of Lys105. Mean-
while, compound 25SPH1-103-433 (Figure 5c) forms five
hydrogen bonds between oxygen O31 and the carbonyl
oxygen atom of Ser56, oxygen O32 and the side chain
oxygen atom of Asp131, oxygen O27 and the side chain
nitrogen atom of Arg84, oxygen O30 and the backbone
nitrogen atom of Trp87, as well as the backbone nitrogen
atom of Gly86. In addition, several hydrophobic interac-
tions were found between compound 25SPH1-103-433
and Gly81, Cys82, Gly83, Thr104, Lys105, Phe133, and
Ile147.
Dong et al. [24] suggested that four residues are signifi-
cantly important ligand binding in the SAM binding
pocket: Lys105, His110, Asp131, and Ile147. Three of the
compounds we discovered create one or more interactions
with the four important residues in the SAM binding site.
Compound SPH1-007-088 binds to Lys105, Asp131, and
Ile147. Compound SPH1-111-460 binds to Lys105, and
compound 25SPH1-103-433 interacts with Lys105,
Asp131, and Ile147. Our results indicate that these three
compounds can block the SAM binding site by binding to
its critical residues.
Discussion
Dengue and DHF remain pharmacologically neglected dis-
eases [25] despite the high mortality rate, especially in
developing countries where access to healthcare facilities
is limited. Economic arguments have hampered the pro-
gress in discovering effective therapies for dengue [26].
T h ef a c tt h a td e n g u ep r i m a r i l ya f f e c t sp o o rc o m m u n i t i e s
prevents many pharmaceutical companies from making a
serious effort to find the cure for this disease. Therefore,
our research group has taken an initiative to be involved
in the discovery of dengue chemotherapy by utilizing a
limited laboratory setting similar to those commonly
found in many developing countries.
We chose to perform a virtual screen of more than 5
million commercially available chemical compounds for
two reasons. First, the cost of a screening campaign is
sometimes prohibitive for laboratories in poor countries
[27]. Therefore, virtual screening using computational
methods may be performed to complement the “real”
high-throughput screening (HTS) in less-funded
laboratories. However, this approach has several disadvan-
tages compared to HTS. For example, receptor flexibility
is sometimes ignored in order to speed-up the computa-
tional screening. Second, the “drug universe” (including all
the possible drug-like molecules) consists of 10
62 mole-
cules [28]. Thus, it is likely that potential molecules for
dengue chemotherapy can be identified from the large
universe of chemical compounds. To find potential che-
motherapeutic compounds, the best strategy is not to
synthesizing more compounds, but rather to use screening
strategies to reduce the size of the molecular universe, as
eloquently stated by Lahana in 1999: “when trying to find
a needle in a haystack, the best strategy might not be to
increase the size of the haystack” [28].
Performing virtual screening from a large database of
chemical compounds requires access to multiprocessor
computers, either in cluster or grid-based architectures.
Research institutions in developed countries have
launched a number of grid-based drug discovery efforts
[29-31]; however, similar facilities often do not exist in
developing countries. This fact motivated us to utilize two
web-based drug-like compound databases (EDULISS and
LIDAEUS) for the screening of commercially available
chemical compounds as potential inhibitors of dengue
NS5 MTase. The compounds screened from both data-
bases were subsequently ranked based on their binding
affinities to NS5 MTase using AutoDock Vina run on a
single personal computer. The settings used in our experi-
ments are suitable for most laboratories in developing
countries with facilities that are inadequate for HTS and
limited access to powerful multiprocessor computers.
In this work, we discovered several compounds that
are potentially able to block the interaction between
dengue NS5 MTase and its substrates, suggested that
t h e ym a yb ea b l et os t o pt h eD Vf r o mr e p l i c a t i n g .T h e
selection of potential compounds was based on their
binding affinities. Compounds with stronger binding
affinities for the RNA cap and SAM binding sites than
that of SAH and RTP (NS5 MTase active ligands) were
selected as potential inhibitors. In addition, the selected
compounds must interact with residues that are catalyti-
cally important for the function of NS5 MTase. The
mode of interaction between the compounds with the
highest affinities and their binding sites was also dis-
cussed in detail.
RNA cap site
It has been suggested that nucleoside analogues are
among the best NS5 MTase inhibitors. These compounds
are expected to bind to the RNA binding site based on
the fact that the strongest interaction between guano-
sine-5′-triphosphate (GTP, the natural substrate for NS5
MTase) and the RNA cap site is formed by π-π stacking
Lim et al. BMC Bioinformatics 2011, 12(Suppl 13):S24
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Ribavirin, a nucleoside analogue and a broad antiviral
agent, has been shown to inhibit the replication of several
DNA and RNA viruses [32], including the DV, although
with weak activity (EC50 of 49 µg/mL) [33]. Ribavirin tri-
phosphate (RTP) has also been shown to inhibit dengue
NS5 MTase with low activity [34]. Figure 3a shows that
RTP forms π-π stacking between Phe25 and the pseudo-
base moiety of RTP. Other nucleoside analogues have
also been synthesized as antiviral agents, such as 5-ethy-
nyl-1-b-D-ribofuranosylimidazole-4-carboxyamide [35],
and 7-deaza-2′-C-methyladenosine [36].
Our screening results show that none of the discovered
compounds can be classified as nucleoside analogues.
Nevertheless, the three compounds (SPH1-103-799,
SPH1-101-102, and 28SPH1-115-917) show better bind-
ing to the RNA cap site than RTP, as indicated by their
binding affinities. Our results are in agreement with
other findings showing that molecules without nucleo-
side moieties may have biological activity against NS5
MTase. Aurintricarboxylic acid was determined to be a
potential inhibitor at the RNA cap site of NS5 MTase by
binding tightly to Lys61 [37], a residue necessary for cor-
rect 2′-O methylation of the RNA [15]. Interestingly, this
compound binds to the two binding sites on NS5 MTase
(RNA cap site and SAM binding site) with different IC50
values (2.3 and 127 µM, respectively) [37]. Podvinec et al.
also suggested two non-nucleoside analogues that act as
potential inhibitors of NS5 MTase by binding to the
RNA cap site with IC50 values of 4.9 and 7.1 µM [31].
SAM binding site
In contrast to the RNA cap site, the SAM binding site is
rather closed and long. This has hindered the development
of several SAM analogues as NS5 MTase inhibitors, pre-
sumably due to off-target activity of the compounds
[38,39]. Efforts have been made to overcome this problem.
For example, Lim et al. synthesized SAH derivatives that
bind selectively to the SAM binding site at submicromolar
concentrations. These compounds are thought to specifi-
cally bind to dengue NS5 MTase and do not interfere with
related human enzymes [40].
It has been suggested that the guanosine moiety is
important for promoting the activity of inhibitors that
bind to the SAM binding site due to the strong hydropho-
bic contacts between the guanosine ring and Lys105 and
Ile147 [24]. Nevertheless, Podvinec et al. reported that two
compounds with no guanosine moiety bound to the SAM
binding site (IC50 of 4.4 and 9.5 µM) [31]. Our results con-
firm the findings by Podvinec et al. in that none of
the compounds we discovered contain a guanosine moiety.
All three compounds (SPH1-007-088, SPH1-111-460,
and 25SPH1-103-433) bind to the SAM binding site by
interacting with several residues important for MTase
activity, such as Lys105, Asp131, and Ile147 [24].
Interestingly, the aromatic rings of compounds SPH1-
007-088 and 25SPH1-103-433 create hydrophobic con-
tacts with Phe133 (Figure 5a and 5c). Phe133 was not
identified as one of the important residues for MTase cata-
lytic activity by Dong et al [24]. However, in their recent
publication, Lim et al. [40] identified a new hydrophobic
cavity that consists of residues Phe133, Ile147, Gly148,
Glu149, Arg160, Arg163, Val164, and Leu182. Phe133
blocks the SAM binding site in its native conformation,
and this residue flips away from the cavity by 100 degrees
upon binding to larger substrates. Compounds SPH1-007-
088 and 25SPH1-103-433 bind to Phe133, suggesting that
these compounds may restrain or prevent the hydrophobic
cavity of the SAM binding site from opening.
Conclusions
We have discovered several potential inhibitory com-
pounds of dengue virus NS5 MTase through virtual
screening using structure-based and ligand-based methods.
These compounds were predicted to bind to the SAM and
RNA cap sites with higher affinities than SAH and RTP.
These compounds are commercially available and can be
easily purchased for further biological activity tests.
All of the compounds we discovered in this work bind
to their respective binding sites by creating hydrogen
bonds and hydrophobic interactions with important resi-
dues in the binding pockets. We performed a detailed ana-
lysis of the atomic interactions between each potential
compound and residues inside the SAM binding site and
RNA cap site to identify which residues interact with the
compounds. We have shown that the interaction between
all compounds with the SAM binding site and RNA cap
site are facilitated by hydrogen bonds and hydrophobic
contacts with residues that are vital for NS5 MTase cataly-
tic function. Therefore, these compounds may be used as
leads for developing an effective dengue drug.
Our virtual screening experiments were performed in a
laboratory setting that is commonly found in many devel-
oping countries. We decided not to develop an expensive
multiprocessor computer architecture. Rather we utilized
two free, web-based drug-like chemical compound data-
bases (LIDAEUS and EDULISS) and the freely available
docking program AutoDock Vina. The new algorithm
implemented in AutoDock Vina permits the high-through-
put docking of thousands of compounds in a shorter time
compared to the classical AutoDock program. Thus, it only
requires a single personal computer. Similar experiments
can be carried out in laboratories with limited funding and
facilities. Therefore, we hope that more researchers in
developing countries can be actively involved in the global
effort to fight dengue infection.
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Software and program
PyMol (DeLano Scientific LLC, USA) and DS Visualizer
(Accelrys, Inc., USA) were employed to visualize and mod-
ify the receptor and ligand structures. A molecular format
conversion program, OpenBabelGUI, was used to prepare
ligands for virtual screening and docking processes. The
LIDAEUS (LIgand Discovery At Edinburgh UniverSity)
[22] program was used to search for potential inhibitors
based on a map of the NS5 MTase binding site by screen-
ing approximately 5 million commercially available chemi-
cal compounds. EDULISS (EDinburgh University LIgand
Selection System) [23] is a chemical compound database
that was used throughout this study to screen for potential
inhibitors based on structural similarities with the known
natural NS5 MTase substrates RTP and SAH. AutoDock
Vina [41] was the primary docking program used in this
work. The preparation of the MTase pdbqt file and deter-
mination of the grid box size were carried out using Auto-
Dock Tools version 1.5.4 (The Scripps Research Institute,
La Jolla, USA). The PaDel-ADV program (Department of
Pharmacy, National University of Singapore, Singapore)
was utilized as the interface to perform molecular docking
of the chemical compounds obtained from LIDAEUS and
EDULISS using AutoDock Vina. Post-docking analyses
were carried out using the Program of Energetic Analysis
o fR e c e p t o rL i g a n dS y s t e m( P E A R L S )[ 4 2 ]a n dL i g P l o t
[43].
Preparation of NS5 MTase structure
The three-dimensional structure of NS5 MTase com-
plexed with S-adenosyl-L-homocysteine (SAH) and riba-
virin (RTP) was retrieved from the Protein Data Bank
[PDB:1R6A]. The NS5 MTase structure was prepared for
structure-based virtual screening and molecular docking
processes by removing all sulfate ions and water mole-
cules. Ligands (SAH and RTP) were removed and saved
as two separate pdb files for further ligand-based virtual
screening and control docking.
Structure-based virtual screening
The web-based program LIDAEUS (http://opus.bch.ed.ac.
uk/lidaeus/index.php) [22] was utilized to search for poten-
tial inhibitors against NS5 MTase by matching the binding
site map of the receptor against chemical compounds in
the database. First, the NS5 MTase structure was uploaded
into LIDAEUS followed by SAH and RTP separately.
LIDAEUS generated an energy map and site points on the
MTase structure based on the positions where SAH and
RTP reside in their binding pockets (the SAM binding site
and RNA cap binding site, respectively). Then, approxi-
mately 5 million compounds were screened, and the top
500 compounds were saved for further molecular docking.
Ligand-based virtual screening
Virtual screening based on the structure of NS5 MTase
active ligands (SAH and RTP) was carried out using the
web-based EDULISS program (http://eduliss.bch.ed.ac.
uk/) [23]. Two-dimensional structures of SAH and RTP
were used to search for similar compounds in the EDU-
LISS database from the most common chemical suppliers
(ChemBridge, MayBridge, PubChem, Sigma-Aldrich,
Salor, Fluka and Specs), covering approximately one mil-
lion chemical compounds. The concept of the similarity
search employed in EDULISS is based on Ultra Fast
Shape Recognition with Atom Types (UFSRAT) [44].
The top 500 compounds with the highest structural simi-
larity to SAH and RTP were used for further molecular
docking analysis.
Molecular docking
Molecular docking was performed using AutoDock Vina
[41]. Autodock Vina was used due to its accuracy and it
speed, which is approximately two orders of magnitude
faster than its predecessor, AutoDock 4 [45]. AutoDock
Tools was utilized to prepare the input pdbqt file for NS5
MTase and to set the size and the center of the grid box.
Kollman charges and polar hydrogen atoms were added
to the NS5 MTase structure. Because NS5 MTase con-
tains two active sites, the grid box cavity size and center
were set separately for both sites. The RNA cap site was
set at 15.180 × -51.931 × 17.429 in the dimensions of x, y
and z using 1.000Å spacing, while the SAM binding site
was set at 18.002 × -43.995 × -1.503 using 1.000Å spa-
cing. AutoDock Vina requires the pdbqt input files of
ligands to be prepared using AutoDock Tools. Due to the
number of molecules to be docked (2000 compounds),
the PaDel-ADV program was utilized to automate the
docking process and act as an interface to perform the
molecular docking of those compounds using AutoDock
Vina. The predicted binding affinity (kcal/mol), which
indicates how strongly a ligand binds to the receptor, is
calculated based on the scoring function used in Auto-
Dock Vina. A more negative binding affinity indicates
stronger binding. The scoring function in AutoDock
Vina is divided into two parts: i) a conformation-depen-
dent part that can be seen as a sum of intramolecular
and intermolecular contributions, including steric, hydro-
phobic, and hydrogen bonding interactions, and ii) a con-
formation-independent part that depends on the number
of rotatable bonds between heavy atoms in the ligand.
Each contribution (steric, hydrophobic, hydrogen bond-
ing, and number of rotatable bonds) is given a different
weight in the AutoDock Vina scoring function [41]. The
validation of docking was carried out by redocking the
NS5 MTase active ligands (SAH and RTP) into their
binding sites. The Program of Energetic Analysis of
Lim et al. BMC Bioinformatics 2011, 12(Suppl 13):S24
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Page 10 of 12Receptor Ligand System (PEARLS) and LigPlot programs
were used to do post-docking analyses.
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